- EOS, Medarex develop and market antibody therapeutics
- Eos licenses Medarex's HuMAb technology
- Raven Biotechnologies licenses Medarex's HuMab-Mouse
- B Twelve, Medarex to develop cancer therapeutics
- IDM and Medarex in product alliance
- IDM and Medarex ally in antibodies and cancer vaccine
- Medarex may license Immuno-Designed Molecules' MAK cells
- Medarex, investors, found Danish biotech Genmab
- Medarex generates antibodies for Northwest's cancer targets
- Northwest Biotherapeutics completes $17.3mm IPO
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.